198 related articles for article (PubMed ID: 38265489)
1. Transcriptomic and epigenetic dissection of spinal ependymoma (SP-EPN) identifies clinically relevant subtypes enriched for tumors with and without NF2 mutation.
Neyazi S; Yamazawa E; Hack K; Tanaka S; Nagae G; Kresbach C; Umeda T; Eckhardt A; Tatsuno K; Pohl L; Hana T; Bockmayr M; Kim P; Dorostkar MM; Takami T; Obrecht D; Takai K; Suwala AK; Komori T; Godbole S; Wefers AK; Otani R; Neumann JE; Higuchi F; Schweizer L; Nakanishi Y; Monoranu CM; Takami H; Engertsberger L; Yamada K; Ruf V; Nomura M; Mohme T; Mukasa A; Herms J; Takayanagi S; Mynarek M; Matsuura R; Lamszus K; Ishii K; Kluwe L; Imai H; von Deimling A; Koike T; Benesch M; Kushihara Y; Snuderl M; Nambu S; Frank S; Omura T; Hagel C; Kugasawa K; Mautner VF; Ichimura K; Rutkowski S; Aburatani H; Saito N; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):22. PubMed ID: 38265489
[TBL] [Abstract][Full Text] [Related]
2. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas.
Ebert C; von Haken M; Meyer-Puttlitz B; Wiestler OD; Reifenberger G; Pietsch T; von Deimling A
Am J Pathol; 1999 Aug; 155(2):627-32. PubMed ID: 10433955
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas.
von Haken MS; White EC; Daneshvar-Shyesther L; Sih S; Choi E; Kalra R; Cogen PH
Genes Chromosomes Cancer; 1996 Sep; 17(1):37-44. PubMed ID: 8889505
[TBL] [Abstract][Full Text] [Related]
4. Molecular genetic alterations on chromosomes 11 and 22 in ependymomas.
Lamszus K; Lachenmayer L; Heinemann U; Kluwe L; Finckh U; Höppner W; Stavrou D; Fillbrandt R; Westphal M
Int J Cancer; 2001 Mar; 91(6):803-8. PubMed ID: 11275983
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity within the PF-EPN-B ependymoma subgroup.
Cavalli FMG; Hübner JM; Sharma T; Luu B; Sill M; Zapotocky M; Mack SC; Witt H; Lin T; Shih DJH; Ho B; Santi M; Emery L; Hukin J; Dunham C; McLendon RE; Lipp ES; Gururangan S; Grossbach A; French P; Kros JM; van Veelen MC; Rao AAN; Giannini C; Leary S; Jung S; Faria CC; Mora J; Schüller U; Alonso MM; Chan JA; Klekner A; Chambless LB; Hwang EI; Massimino M; Eberhart CG; Karajannis MA; Lu B; Liau LM; Zollo M; Ferrucci V; Carlotti C; Tirapelli DPC; Tabori U; Bouffet E; Ryzhova M; Ellison DW; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Pfister SM; Taylor MD; Aldape K; Pajtler KW; Kool M; Ramaswamy V
Acta Neuropathol; 2018 Aug; 136(2):227-237. PubMed ID: 30019219
[TBL] [Abstract][Full Text] [Related]
6. MYCN amplification drives an aggressive form of spinal ependymoma.
Ghasemi DR; Sill M; Okonechnikov K; Korshunov A; Yip S; Schutz PW; Scheie D; Kruse A; Harter PN; Kastelan M; Wagner M; Hartmann C; Benzel J; Maass KK; Khasraw M; Sträter R; Thomas C; Paulus W; Kratz CP; Witt H; Kawauchi D; Herold-Mende C; Sahm F; Brandner S; Kool M; Jones DTW; von Deimling A; Pfister SM; Reuss DE; Pajtler KW
Acta Neuropathol; 2019 Dec; 138(6):1075-1089. PubMed ID: 31414211
[TBL] [Abstract][Full Text] [Related]
7. High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma.
Raffeld M; Abdullaev Z; Pack SD; Xi L; Nagaraj S; Briceno N; Vera E; Pittaluga S; Lopes Abath Neto O; Quezado M; Aldape K; Armstrong TS; Gilbert MR
Acta Neuropathol Commun; 2020 Jul; 8(1):101. PubMed ID: 32641156
[TBL] [Abstract][Full Text] [Related]
8. Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomas.
Pohl LC; Leitheiser M; Obrecht D; Schweizer L; Wefers AK; Eckhardt A; Raffeld M; Sturm D; Pajtler KW; Rutkowski S; Fukuoka K; Ichimura K; Bockmayr M; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):24. PubMed ID: 38265522
[TBL] [Abstract][Full Text] [Related]
9. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.
Fukuoka K; Kanemura Y; Shofuda T; Fukushima S; Yamashita S; Narushima D; Kato M; Honda-Kitahara M; Ichikawa H; Kohno T; Sasaki A; Hirato J; Hirose T; Komori T; Satomi K; Yoshida A; Yamasaki K; Nakano Y; Takada A; Nakamura T; Takami H; Matsushita Y; Suzuki T; Nakamura H; Makino K; Sonoda Y; Saito R; Tominaga T; Matsusaka Y; Kobayashi K; Nagane M; Furuta T; Nakada M; Narita Y; Hirose Y; Ohba S; Wada A; Shimizu K; Kurozumi K; Date I; Fukai J; Miyairi Y; Kagawa N; Kawamura A; Yoshida M; Nishida N; Wataya T; Yamaoka M; Tsuyuguchi N; Uda T; Takahashi M; Nakano Y; Akai T; Izumoto S; Nonaka M; Yoshifuji K; Kodama Y; Mano M; Ozawa T; Ramaswamy V; Taylor MD; Ushijima T; Shibui S; Yamasaki M; Arai H; Sakamoto H; Nishikawa R; Ichimura K;
Acta Neuropathol Commun; 2018 Dec; 6(1):134. PubMed ID: 30514397
[TBL] [Abstract][Full Text] [Related]
10. Clinically relevant molecular hallmarks of PFA ependymomas display intratumoral heterogeneity and correlate with tumor morphology.
Gödicke S; Kresbach C; Ehlert M; Obrecht D; Altendorf L; Hack K; von Hoff K; Carén H; Melcher V; Kerl K; Englinger B; Filbin M; Pajtler KW; Gojo J; Pietsch T; Rutkowski S; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):23. PubMed ID: 38265527
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of histopathological ependymoma variants.
Neumann JE; Spohn M; Obrecht D; Mynarek M; Thomas C; Hasselblatt M; Dorostkar MM; Wefers AK; Frank S; Monoranu CM; Koch A; Witt H; Kool M; Pajtler KW; Rutkowski S; Glatzel M; Schüller U
Acta Neuropathol; 2020 Feb; 139(2):305-318. PubMed ID: 31679042
[TBL] [Abstract][Full Text] [Related]
12. A deletion causing NF2 exon 9 skipping is associated with familial autosomal dominant intramedullary ependymoma.
Zemmoura I; Vourc'h P; Paubel A; Parfait B; Cohen J; Bilan F; Kitzis A; Rousselot C; Parker F; François P; Andres CR
Neuro Oncol; 2014 Jan; 16(2):250-5. PubMed ID: 24357459
[TBL] [Abstract][Full Text] [Related]
13. Ependymomas of the spinal region in adults: Clinical and pathological features and MYCN expression levels in spinal ependymomas and myxopapillary ependymomas.
Topel G; Dirilenoğlu F; Sevin İE; Kahraman A
Ann Diagn Pathol; 2024 Jun; 70():152299. PubMed ID: 38555652
[TBL] [Abstract][Full Text] [Related]
14. Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas.
Shatara M; Schieffer KM; Klawinski D; Thomas DL; Pierson CR; Sribnick EA; Jones J; Rodriguez DP; Deeg C; Hamelberg E; LaHaye S; Miller KE; Fitch J; Kelly B; Leraas K; Pfau R; White P; Magrini V; Wilson RK; Mardis ER; Abdelbaki MS; Finlay JL; Boué DR; Cottrell CE; Ghasemi DR; Pajtler KW; Osorio DS
Acta Neuropathol Commun; 2021 Dec; 9(1):192. PubMed ID: 34895332
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus.
Hansson CM; Buckley PG; Grigelioniene G; Piotrowski A; Hellström AR; Mantripragada K; Jarbo C; Mathiesen T; Dumanski JP
BMC Genomics; 2007 Jan; 8():16. PubMed ID: 17222329
[TBL] [Abstract][Full Text] [Related]
16. Integrative molecular characterization of pediatric spinal ependymoma: the UK Children's Cancer and Leukaemia Group study.
Ahmad O; Chapman R; Storer LC; Luo L; Heath PR; Resar L; Cohen KJ; Grundy RG; Lourdusamy A
Neurooncol Adv; 2021; 3(1):vdab043. PubMed ID: 34041479
[TBL] [Abstract][Full Text] [Related]
17. Cerebral and spinal cord tanycytic ependymomas in a young adult with a mutation in the NF2 gene.
Kuga Y; Ohnishi H; Kodama Y; Takakura S; Hayashi M; Yagi R; Fukutome K; Matsushima K; Okamoto K; Taomoto K; Takahashi H
Neuropathology; 2014 Aug; 34(4):406-13. PubMed ID: 24612193
[TBL] [Abstract][Full Text] [Related]
18. Indications for a tumor suppressor gene at 22q11 involved in the pathogenesis of ependymal tumors and distinct from hSNF5/INI1.
Kraus JA; de Millas W; Sörensen N; Herbold C; Schichor C; Tonn JC; Wiestler OD; von Deimling A; Pietsch T
Acta Neuropathol; 2001 Jul; 102(1):69-74. PubMed ID: 11547953
[TBL] [Abstract][Full Text] [Related]
19. Adult intracranial ependymoma-relevance of DNA methylation profiling for diagnosis, prognosis, and treatment.
Träger M; Schweizer L; Pérez E; Schmid S; Hain EG; Dittmayer C; Onken J; Fukuoka K; Ichimura K; Schüller U; Dührsen L; Müther M; Paulus W; Thomas C; Gutt-Will M; Schucht P; Maragkou T; Schittenhelm J; Eckert F; Niyazi M; Fleischmann DF; Dorostkar MM; Feyer P; May SA; Moskopp D; Badakhshi H; Radke C; Walter J; Ehret F; Capper D; Kaul D
Neuro Oncol; 2023 Jul; 25(7):1286-1298. PubMed ID: 36734226
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
Thomas C; Thierfelder F; Träger M; Soschinski P; Müther M; Edelmann D; Förster A; Geiler C; Kim HY; Filipski K; Harter PN; Schittenhelm J; Eckert F; Ntoulias G; May SA; Stummer W; Onken J; Vajkoczy P; Schüller U; Heppner FL; Capper D; Koch A; Kaul D; Paulus W; Hasselblatt M; Schweizer L
Acta Neuropathol; 2021 Jun; 141(6):959-970. PubMed ID: 33755803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
